Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
Authors:
- Juleen GayedJGJuleen Gayed
- Vishva BangadVBVishva Bangad
- Xia XuXXXia Xu
- Federico MensaFMFederico Mensa
- Mark CutlerMCMark Cutler
- Özlem TüreciÖTÖzlem Türeci
- Uǧur ŞahinUŞUǧur Şahin
- Kayvon ModjarradKMKayvon Modjarrad
- Kena A. SwansonKSKena A. Swanson
- Annaliesa S. AndersonAAAnnaliesa S. Anderson
- Alejandra GurtmanAGAlejandra Gurtman
- Nicholas KitchinNKNicholas Kitchin
Preprint
- 17 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, open-label, phase 2/3 trial of a single 30-μg dose of monovalent Omicron XBB.1.5-adapted BNT162b2 vaccine. Healthy participants had previously received ≥3 doses of a US-authorized mRNA vaccine, with the most recent being a bivalent Omicron BA.4/BA.5-adapted vaccine administered ≥150 days before study vaccination. In this analysis, Omicron XBB.1.5, BA.2.86, and JN.1 serum neutralizing titers were assessed at baseline and 1 month after vaccination in a subset of ≥18-year-olds (N = 40) with evidence of previous SARS-CoV-2 infection. Immunogenicity was also evaluated in a demographically matched group of participants who received bivalent BA.4/BA.5-adapted BNT162b2 in another study (ClinicalTrials.gov Identifier: NCT05472038). The XBB.1.5-adapted BNT162b2 vaccine elicited higher XBB.1.5, BA.2.86, and JN.1 neutralizing titers than those elicited by bivalent BA.4/BA.5-adapted BNT162b2. Overall geometric mean fold rises in neutralizing titers from baseline to 1 month after vaccination were higher among participants who received XBB.1.5-adapted BNT162b2 than those who received bivalent BA.4/BA.5-adapted BNT162b2 for XBB.1.5 (7.6 vs 5.6), slightly higher for JN.1 (3.9 vs 3.5), and similar for BA.2.86 (4.8 vs 4.9). ClinicalTrials.gov Identifier: NCT05997290.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody TitersViruses, 2024
- 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)Eurosurveillance, 2024
- Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialVaccines, 2024
- Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in SwedenThe Lancet Infectious Diseases, 2024
- Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023Eurosurveillance, 2024
- Virological characteristics of the SARS-CoV-2 JN.1 variantThe Lancet Infectious Diseases, 2024
- Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressureThe Lancet Infectious Diseases, 2023
- Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccinationThe Lancet Infectious Diseases, 2023
- Predicting the efficacy of variant-modified COVID-19 vaccine boostersNature Medicine, 2023